Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ULYM18086 / acalabrutinib -Barr IIT / Paul Barr

Research Question:
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

Basic Study Information

Purpose:
The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Location: University of Rochester Medical Center
Study Reference #: ULYM18086

Lead Researcher (Principal Investigator)

Lead Researcher:  Paul Barr

Study Contact Information

Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search